News & Trends - MedTech & Diagnostics
LifeHealthcare appoints new CEO as parent company expands through strategic acquisitions

LifeHealthcare, an EBOS MedTech company, is entering a new phase of growth with the appointment of Paul Petherbridge as CEO. Having spent 15 years with the company, most recently as Chief Commercial Officer, Petherbridge brings deep industry knowledge and strategic vision to his new role.
“We have built strong foundations as a company, and even stronger partnerships with our suppliers; it is on this foundation that I look forward to ensuring that I champion if it’s good for our customers, our people, it will be a good outcome for our business,” Petherbridge said.
As part of his leadership vision, Petherbridge has expanded the LifeHealthcare leadership team, bringing in additional expertise to drive the company forward. The new appointments include Rebecca Payne as Financial Controller, Brenden Grib as General Manager of Product Marketing, and Rachael Sechi as Senior P&C Business Partner.
“These leaders, all of whom have had long careers with LifeHealthcare, not only complement the wider team but also demonstrate the company’s commitment to developing leadership roles from within. This approach ensures that all perspectives, especially those of our people and customers, are heard in our decision-making processes,” Petherbridge added.
LifeHealthcare, a medical technology distribution business, is also strengthening its market position through new service offerings and technology partnerships. The company has introduced a dedicated remote selling team for surgical instruments, is collaborating with Australian Biotechnologies on new products for Plastics and Orthopaedics, and is launching cutting-edge technologies from suppliers such as Proprio.
LifeHealthcare’s growth aligns with the broader success of its parent company, EBOS Group. Over the past decade, EBOS has diversified its portfolio with more than 20 acquisitions spanning medical technology, retail pharmacy, medical consumables, and animal care.
In FY24, EBOS achieved record revenue of over $13 billion, marking a 7.8% increase from the previous year. Growth in its medical technology division was fuelled by strong performance in spine, implant, aesthetics, and allograft channels.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Biotechnology

CSL reshapes R&D while bracing for U.S. tariffs
Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]
MoreNews & Trends - MedTech & Diagnostics

Australia joins Medtronic trial in fight against resistant hypertension
Medtronic has launched an international clinical trial across Australia, the United States, and Europe to evaluate the feasibility of multi-organ […]
MoreNews & Trends - MedTech & Diagnostics

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban
Medibank has become the first Australian health insurer to pay towards pharmacogenetic testing (PGx) for eligible customers on Extras cover. […]
MoreNews & Trends - Pharmaceuticals

Global pledge shifts visibility and action for patients with advanced breast cancer
Three breast cancer organisations have united internationally to demand that people living with metastatic breast cancer (MBC) are no longer […]
More